Induction of mania is same as drug-induced REM-deprived psychosis or BPIII

[Guest guest]

A search of previous posts in this group will yield an understanding

of how SSRI drugs induce mania or BPIII in normal individuals. The

main contributory factor of SSRIs is their ability to unrelentingly

deprive humans of R.E.M. during sleep which causes REM to shift to

wake states along with REM's associated mixed and hallucinatory

mindstates. REM is strongly correlated with hallucinatory mindstates

including normal dreaming in nearly all individuals. In fact, it is

not an understatement to say that we all hallucinate regularly (that

is during sleep). The precise pathophysiology of REM deprived

hallucinatory psychosis has been proven to be linked directly to the

crucial changes of the 10th carbon atom of the rhodopsin retinol

isomer in the eye receptors. This change which is normally associated

with a photon's quantum wave effect upon visual receptors (attenuating

or tuning the normal continual eye-brain signal) is also associated

with intra-ocular fluid pressure changes within the eye from

centrifugal force associated with rapid eye movements back and forth.

In other words, pressure changes in the eye of sleep deprived

individuals causes hallucinations. This same phenomenon is evinced in

other eye maladies related to eye pressure change effects such as

glaucoma patients sometimes experience. Unrelenting REM deprivation,

by any means, for a sufficient period of time causes the same

phenomenon of hallucination. Hallucination is not always perceived as

such by the sufferer as a human interpretive function is also

involved. Perceptions of flashes of light are sometimes known to

occur hours or days prior to hallucination in drug-induced

hallucinatory psychosis. Development of lucid dreaming techniques can

help minimize shifting to drug-induced wake-state hallucination.

http://www.ghuth.com

>

> RESULTS: Seven (8.86%) of the 79 paroxetine-

> treated patients developed mania.

>

>

> Induction of mania in depression by paroxetine.

>

> Morishita S, Arita S.

>

> Department of Psychiatry, Kawasaki Medical School, Kurashiki,

> Okayama, Japan. morisita@

>

> INTRODUCTION: An investigation of the proportion of patients who

> have experienced mania with antidepressant treatment and their

> characteristics would seem to be of clinical use. AIMS: The purpose

> of this clinical study was to examine the predictors of induction of

> mania in depression patients as a result of paroxetine treatment.

> METHOD: A retrospective cohort analysis was carried out among

> depression patients treated in the Department of Psychiatry,

> Kawasaki Medical School Hospital, Kurashiki, Japan, in 2000 and

> 2001. Some 79 patients were identified who were receiving paroxetine

> to treat depression. A variety of clinical factors including gender,

> the type of depression, frequency of episodes, family history, age

> and daily dose were examined as possible predictors of induction of

> mania by paroxetine. RESULTS: Seven (8.86%) of the 79 paroxetine-

> treated patients developed mania. A proportional hazards

> analysis showed the type of depression and the history of family

> psychiatric illness to be independent predictive factors of the

> induction of mania by paroxetine treatment. CONCLUSIONS: The rate of

> mania induction of paroxetine is not substantially different from

> that found for conventional antidepressants. The type of depression

> and the history of family psychiatric illness may be considered as

> predictors of mania induction in depression patients taking

> paroxetine treatment. Copyright 2003 Wiley & Sons, Ltd.

>

> PMID: 14533140 [PubMed - indexed for MEDLINE]

>

> ---------------------------------------------------------------------

> -----------

>